Ipsen is casting a wider BD net under new CEO Loew
French pharma to use $3B war chest to add clinical candidates, late-stage U.S. program
The French pharma is stepping up its pursuit of external innovation to fill out its pipeline with NMEs ahead of generic competition for its best-selling drug.
With a pipeline heavy on line extensions and its bestseller headed toward a patent cliff, new Ipsen CEO David Loew is doubling down on the mid-cap biopharma’s commitment to external innovation. But this time, Ipsen will be looking for programs across a broader range of indications and with a focus on mid-sized, rather than blockbuster, opportunities.
Tipping the scales towards external innovation isn’t a new idea for Ipsen Group (Euronext:IPN).
In 2017, then CEO David Meek had set a course for Ipsen to fill out its clinical pipeline through BD